Danon Disease Due to a Novel LAMP2 Microduplication

  • Matthew A. Lines
  • Stacy Hewson
  • William Halliday
  • Peter J. B. Sabatini
  • Tracy Stockley
  • Anne I. Dipchand
  • Sarah Bowdin
  • Komudi SiriwardenaEmail author
Case Report
Part of the JIMD Reports book series (JIMD, volume 14)


Danon disease is a rare X-linked disorder comprising hypertrophic cardiomyopathy, skeletal myopathy, intellectual disability, and retinopathy; mutations of the lysosome-associated membrane protein gene LAMP2 are responsible. Most affected persons exhibit “private” point mutations; small locus rearrangements have recently been reported in four cases. Here, we describe the clinical, pathologic, and molecular features of a male proband and his affected mother with Danon disease and a small LAMP2 microduplication. The proband presented at age 12 years with exercise intolerance, hypertrophic cardiomyopathy, and increased creatine kinase. Endomyocardial biopsy findings were nonspecific, showing myocyte hypertrophy and reactive mitochondrial changes. Quadriceps muscle biopsy demonstrated the characteristic autophagic vacuoles with sarcolemma-like features. LAMP2 tissue immunostaining was absent; however, LAMP2 sequencing was normal. Deletion/duplication testing by multiplex ligation-dependent probe amplification (MLPA) assay revealed a 1.5kb microduplication containing LAMP2 exons 4 and 5. RT-PCR studies were consistent with the inclusion of these two duplicated exons in the final spliced transcript, resulting in a frameshift. The proband’s mother, who had died following cardiac transplantation due to suspected myocarditis at age 35, was reviewed and was shown to be affected upon immunostaining of banked myocardial tissue. This case constitutes the second report of a pathogenic microduplication in Danon disease, and illustrates a number of potential diagnostic pitfalls. Firstly, given the imperfect sensitivity of LAMP2 sequencing, tissue immunostaining and/or MLPA should be considered as a diagnostic adjunct in the workup for this disorder. Secondly, the pathological findings in myocardium may be falsely indicative of relatively common conditions such as myocarditis.


Intellectual Disability Hypertrophic Cardiomyopathy Endomyocardial Biopsy Pompe Disease Arrhythmogenic Right Ventricular Dysplasia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

327082_1_En_277_MOESM1_ESM.docx (57 kb)
Supplementary Table 1 Progressive hypertrophic cardiomyopathy


  1. Alroy J, Pfannl R, Slavov D, Taylor MR (2010) Electron microscopic findings in skin biopsies from patients with Danon disease. Ultrastruct Pathol 34:333–336PubMedCrossRefGoogle Scholar
  2. Arad M, Maron BJ, Gorham JM et al (2005) Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 352:362–372PubMedCrossRefGoogle Scholar
  3. Bandyopadhyay U, Kaushik S, Varticovski L, Cuervo AM (2008) The chaperone-mediated autophagy receptor organizes in dynamic protein complexes at the lysosomal membrane. Mol Cell Biol 28:5747–5763PubMedCrossRefPubMedCentralGoogle Scholar
  4. Boucek D, Jirikowic J, Taylor M (2011) Natural history of Danon disease. Genet Med 13:563–568PubMedCrossRefGoogle Scholar
  5. Cheng Z, Cui Q, Tian Z et al (2012) Danon disease as a cause of concentric left ventricular hypertrophy in patients who underwent endomyocardial biopsy. Eur Heart J 33:649–656PubMedCrossRefGoogle Scholar
  6. Cuervo AM, Dice JF (1996) A receptor for the selective uptake and degradation of proteins by lysosomes. Science 273:501–503PubMedCrossRefGoogle Scholar
  7. Danon MJ, Oh SJ, DiMauro S (1981) Lysosomal glycogen storage disease with normal acid maltase. Neurology 31:51–57PubMedCrossRefGoogle Scholar
  8. Demirel Ö, Jan I, Wolters D et al (2012) The lysosomal polypeptide transporter TAPL is stabilized by interaction with LAMP-1 and LAMP-2. J Cell Sci 125:4230–4240PubMedCrossRefGoogle Scholar
  9. Fanin M, Nascimbeni AC, Fulizio L, Spinazzi M, Melacini P, Angelini C (2006) Generalized lysosome-associated membrane protein-2 defect explains multisystem clinical involvement and allows leukocyte diagnostic screening in Danon disease. Am J Pathol 168:1309–1320PubMedCrossRefPubMedCentralGoogle Scholar
  10. Fujiwara Y, Furuta A, Kikuchi H et al (2013) Discovery of a novel type of autophagy targeting RNA. Autophagy 9:403–409PubMedCrossRefPubMedCentralGoogle Scholar
  11. González-Polo RA, Boya P, Pauleau AL et al (2005) The apoptosis/autophagy paradox: autophagic vacuolization before apoptotic death. J Cell Sci 118:3091–3102PubMedCrossRefGoogle Scholar
  12. Kaushik S, Bandyopadhyay U, Sridhar S et al (2011) Chaperone-mediated autophagy at a glance. J Cell Sci 124:495–499PubMedCrossRefPubMedCentralGoogle Scholar
  13. Majer F, Pelak O, Kalina T et al (2013) Mosaic tissue distribution of the tandem duplication of LAMP2 exons 4 and 5 demonstrates the limits of Danon disease cellular and molecular diagnostics. J Inh Metab Dis [Epub ahead of print] (PMID: 23716275/doi  10.1007/s10545-013-9617-z)
  14. Miani D, Taylor M, Mestroni L et al (2012) Sudden death associated with danon disease in women. Am J Cardiol 109:406–411PubMedCrossRefGoogle Scholar
  15. Murakami N, Goto Y, Itoh M et al (1995) Sarcolemmal indentation in cardiomyopathy with mental retardation and vacuolar myopathy. Neuromuscul Disord 5:149–155PubMedCrossRefGoogle Scholar
  16. Nishino I, Fu J, Tanji K et al (2000) Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature 406:906–910PubMedCrossRefGoogle Scholar
  17. Sugie K, Noguchi S, Kozuka Y et al (2005) Autophagic vacuoles with sarcolemmal features delineate Danon disease and related myopathies. J Neuropathol Exp Neurol 64:513–522PubMedGoogle Scholar
  18. Tanaka Y, Guhde G, Suter A et al (2000) Accumulation of autophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice. Nature 406:902–906PubMedCrossRefGoogle Scholar
  19. Taylor MR, Ku L, Slavov D et al (2007) Danon disease presenting with dilated cardiomyopathy and a complex phenotype. J Hum Genet 52:830–835PubMedCrossRefGoogle Scholar
  20. van der Kooi AJ, van Langen IM, Aronica E et al (2008) Extension of the clinical spectrum of Danon disease. Neurology 70:1358–1359PubMedCrossRefGoogle Scholar
  21. Yang Z, Funke BH, Cripe LH et al (2010) LAMP2 microdeletions in patients with Danon disease. Circ Cardiovasc Genet 3:129–137PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© SSIEM and Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Matthew A. Lines
    • 1
  • Stacy Hewson
    • 2
  • William Halliday
    • 3
  • Peter J. B. Sabatini
    • 3
  • Tracy Stockley
    • 3
  • Anne I. Dipchand
    • 4
  • Sarah Bowdin
    • 2
  • Komudi Siriwardena
    • 2
    Email author
  1. 1.Division of Metabolics and Newborn ScreeningChildren’s Hospital of Eastern OntarioOttawaCanada
  2. 2.Department of Clinical and Metabolic GeneticsThe Hospital for Sick ChildrenTorontoCanada
  3. 3.Department of Pediatric Laboratory MedicineThe Hospital for Sick ChildrenTorontoCanada
  4. 4.Department of CardiologyThe Hospital for Sick ChildrenTorontoCanada

Personalised recommendations